期刊文献+

盐酸雷洛昔芬的合成改进 被引量:3

Improved synthesis of raloxifene hydrochloride
下载PDF
导出
摘要 目的:优化盐酸雷洛昔芬的合成路线。方法:以3-甲氧基苯硫酚和4-甲氧基-α-溴代苯乙酮为起始原料,经取代反应,环合反应得到6-甲氧基-2-(4-乙酰氧基苯基)苯并[b]噻吩,再与4-[2-(1-哌啶基)乙氧基]苯甲酰氯盐酸盐发生Friedel-Crafts反应,然后发生脱甲基反应,最后经成盐反应,共5步主要反应制得目标产物。结果:目标化合物结构经红外光谱、核磁共振氢谱及质谱确证。结论:本方法反应条件温和,操作简便,并且提高了产率。 Objective:To optimize the synthetic route of raloxifene hydrochloride.Methods:The target compound was synthesized from 3- methoxybenzenethiol and 4- methoxy-α- bromo acetophenone via five steps, including substitution, cyclization, Friedel-Crafts reaction, demethyl reaction and salt formation. Results: The structure of the target compound was confirmed by IR, ^1 H-NMR and MS. Conclusion: This synthetic route had a mild reaction condition and improved yield,and was easily controlled.
出处 《中国新药杂志》 CAS CSCD 北大核心 2005年第7期882-884,共3页 Chinese Journal of New Drugs
关键词 盐酸雷洛昔芬 合成路线 骨质疏松 药物治疗 raloxifene hydrochloride synthetic route osteoporosis
  • 相关文献

参考文献5

二级参考文献17

  • 1[13](a)Eur Pat Appl EP 6171030 (CL C07D333/56), 28 Sep 1994. (b)Int pat Appl Ep707,852 (CL A61K31/40) 21 Apr 1996.
  • 2[14]Dodge JA, Lugar CW, Cho S, et al. Evaluation of the major metablites of raloxifene as modulator of tissue selectivity. J Steroid Biochem Molec Biol, 1997, 61:97
  • 3[15]Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci, 1997, 94(25):14105
  • 4[16]Yang NN, Venugopala M, Hardikar S, et al. Identification of estrogen response element activated by metablites of 17-β-estradiol and raloxifene. Science, 1996, 273(753):1222
  • 5[17]Bryant HU, Dere UH. SERMs, Multiple pathway for ER responses. Proc Soc Exp Biol Med, 1998, 217(1):45
  • 6[1]Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. Structure-activity studies in a series of 3-Kroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]menthanone hydrochloride (LY156758), a remarkablely effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem, 1984, 27:1057
  • 7[2]Thompson EW, Reich R, Shima TB, et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res, 1988, 48:6764
  • 8[3]Anzano MA, Peer CW, Smith JM, et al. Chemprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinic acid. J Nat'l Cancer Inst, 1996, 88(2):123
  • 9[4]Zuckerman SH, Bryan N. Inhibition of LDL oxidationa and myeloperoxidase dependent tyrosl radical formation by the selective estrogen receptor modulator raloxifene (LY 139481 HCL). Atherosclerosis, 1996, 126:65
  • 10[5]Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest, 1994, 93:63

共引文献41

同被引文献17

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部